BRCA1 and breast cancer: Subsequently, the NEOTALA study tested talazoparib monotherapy preoperatively in BRCA1/2 mutated HER2 negative breast cancers showing pCR rates of 49%, which is numerically comparable to those receiving neoadjuvant chemotherapy [69].